Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Sorafenib vs Docetaxel + Placebo in First-Line HER2-Negative Metastatic Breast Cancer
2008-001090-15Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Docetaxel + Sorafenib with Docetaxel + Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jul 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-001090-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001090-15.